Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9593485 | 0.85 | RAB9A (0.57) | SMN1; SMN2RAB9ANPC1MAPTHPGD | |
| SCHEMBL2131964 | 0.82 | TP53 (0.50) | SMN1; SMN2THRBTP53SMYD3RAB9A | |
| SCHEMBL3066466 | 0.82 | ALDH1A1 (0.42) | SMN1; SMN2THRBRAB9ANPC1MAPT | |
| SCHEMBL2619071 | 0.80 | THRB (0.48) | SMN1; SMN2THRBTP53SMYD3RAB9A | |
| SCHEMBL9817341 | 0.80 | RAB9A (0.37) | SMN1; SMN2SMYD3RAB9ANPC1MAPT | |
| SCHEMBL11533407 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2THRBTP53SMYD3RAB9A | |
| SCHEMBL3066648 | 0.79 | ALDH1A1 (0.60) | SMN1; SMN2TP53RAB9ANPC1MAPT | |
| SCHEMBL21939043 | 0.77 | THRB (0.56) | SMN1; SMN2THRBTP53SMYD3RAB9A | |
| SCHEMBL14069154 | 0.77 | THRB (0.56) | SMN1; SMN2THRBTP53SMYD3RAB9A | |
| SCHEMBL18255998 | 0.77 | MRGPRX4 (0.52) | SMN1; SMN2THRBTP53SMYD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552918-B1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2552918-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-0378111-B1 | Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them | ZAMBON SPA (IT) | 1994-06-01 | — | — | EP | disclosed |
| US-4988691-A | Analgesics, cardiovascular disorders, nervous system disorders | ZAMBON GROUP S.P.A. (IT) | 1991-01-29 | — | — | US | disclosed |
| EP-0378111-A1 | Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them | ZAMBON GROUP S.p.A. (IT) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | SMN1; SMN2 1594/4885THRB 2443/4885TP53 4687/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SMN1; SMN2 4/4885THRB 2602/4885TP53 4360/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SMN1; SMN2 4/4885THRB 2602/4885TP53 4360/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SMN1; SMN2 4/4885THRB 2602/4885TP53 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.